-
Something wrong with this record ?
Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis
J. Schneider-Thoma, T. Hamza, K. Chalkou, S. Siafis, S. Dong, I. Bighelli, WP. Hansen, E. Scheuring, JM. Davis, J. Priller, P. Baumann, R. Conley, J. Cordes, D. Kelly, M. Kluge, S. Kumra, S. Lewis, HY. Meltzer, D. Naber, N. Schooler, J. Volavka,...
Language English Country England, Great Britain
Document type Journal Article, Systematic Review, Meta-Analysis
- MeSH
- Antipsychotic Agents * therapeutic use MeSH
- Adult MeSH
- Clozapine * therapeutic use MeSH
- Humans MeSH
- Randomized Controlled Trials as Topic MeSH
- Schizophrenia, Treatment-Resistant * drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Systematic Review MeSH
BACKGROUND: Clozapine is recommended by national and international guidelines for people with treatment-resistant schizophrenia. However, available meta-analyses of randomised controlled trials have not shown superior efficacy of clozapine when compared with other second-generation antipsychotics, with heterogeneity identified between the original studies. We aimed to use individual patient data (IPD) to account for potential reasons of variability and to synthesise an adjusted estimate for the difference in efficacy between clozapine and other second-generation antipsychotics for treatment-resistant schizophrenia. METHODS: In this systematic review and IPD meta-analysis, we searched the Cochrane Schizophrenia Group's Study-Based Register from inception to Jan 24, 2024, and previous reviews for blinded randomised controlled trials comparing clozapine with other second-generation antipsychotics in participants with treatment-resistant schizophrenia. Trials were eligible if they included patients with treatment-resistant schizophrenia and had a duration of at least 6 weeks. IPD were requested from trial investigators. The primary outcome was change in overall schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) between clozapine and other second-generation antipsychotics after 6-8 weeks of treatment. The effect size measure for the primary outcome was mean difference with 95% credible interval (CrI). We fitted a Bayesian random-effects IPD meta-regression model that included duration of illness, baseline severity, and sex as potential prognostic factors or treatment effect modifiers. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). People with lived experience of mental illness were involved in this study. This study is registered with PROSPERO, CRD42021254986. FINDINGS: We screened 13 876 references and included 19 studies with data for 1599 participants; IPD were available for 12 of 19 trials (n=1052; mean age 37·67 years [SD 11·24; range 10-66]; 348 [33·08%] women and 704 [66·92%] men). Data on ethnicity were not available. The estimated mean difference in change from baseline PANSS total score was -0·64 points (95% CrI -3·97 to 2·63; τ=2·68) in favour of other second-generation antipsychotics. Shorter duration of illness and higher baseline severity were prognostic factors associated with a larger reduction in symptoms, but neither those factors nor sex were found to modify the relative effect between clozapine and other second-generation antipsychotics. The confidence in the evidence was graded as very low. INTERPRETATION: This IPD meta-analysis found a small and uncertain advantage of other second-generation antipsychotics, mainly olanzapine and risperidone, and so did not provide evidence for superior efficacy of clozapine compared with other second-generation antipsychotics in treatment-resistant schizophrenia. It is limited by unavailability of IPD for some studies, uncaptured sources of variance, and uncertainty due to premature study discontinuation. Given the side-effects of clozapine, the observed uncertainty regarding clozapine's superiority warrants prudent use and further research. FUNDING: German Ministry of Education and Research.
Bündnis für psychisch erkrankte Menschen Munich Germany
Department of Clinical Research University of Bern Bern Switzerland
Department of Psychiatry and Behavioral Sciences University of Minnesota Minneapolis MN USA
Department of Psychiatry and Psychotherapy Florence Nightingale Hospital Düsseldorf Germany
Department of Psychiatry and Psychotherapy Hamburg Eppendorf University Hamburg Germany
Department of Psychiatry and Psychotherapy University of Leipzig Leipzig Germany
Faculty of Biology Medicine and Health The University of Manchester Manchester UK
Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Finnish Institute for Health and Welfare Helsinki Finland
German Center for Mental Health Munich Germany
Graduate School for Health Sciences University of Bern Bern Switzerland
Institute of Social and Preventive Medicine University of Bern Bern Switzerland
Maryland Psychiatric Research Center Baltimore MD USA
Psychiatric Institute University of Illinois at Chicago Chicago IL USA
School of Medicine University of Maryland Baltimore MD USA
SUNY Downstate Health Sciences Center New York NY USA
University of Edinburgh and UK Dementia Research Institute Edinburgh UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009328
- 003
- CZ-PrNML
- 005
- 20250429135439.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2215-0366(25)00001-X $2 doi
- 035 __
- $a (PubMed)40023172
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Schneider-Thoma, Johannes $u Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany; German Center for Mental Health, Munich, Germany
- 245 10
- $a Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis / $c J. Schneider-Thoma, T. Hamza, K. Chalkou, S. Siafis, S. Dong, I. Bighelli, WP. Hansen, E. Scheuring, JM. Davis, J. Priller, P. Baumann, R. Conley, J. Cordes, D. Kelly, M. Kluge, S. Kumra, S. Lewis, HY. Meltzer, D. Naber, N. Schooler, J. Volavka, K. Wahlbeck, G. Salanti, S. Leucht
- 520 9_
- $a BACKGROUND: Clozapine is recommended by national and international guidelines for people with treatment-resistant schizophrenia. However, available meta-analyses of randomised controlled trials have not shown superior efficacy of clozapine when compared with other second-generation antipsychotics, with heterogeneity identified between the original studies. We aimed to use individual patient data (IPD) to account for potential reasons of variability and to synthesise an adjusted estimate for the difference in efficacy between clozapine and other second-generation antipsychotics for treatment-resistant schizophrenia. METHODS: In this systematic review and IPD meta-analysis, we searched the Cochrane Schizophrenia Group's Study-Based Register from inception to Jan 24, 2024, and previous reviews for blinded randomised controlled trials comparing clozapine with other second-generation antipsychotics in participants with treatment-resistant schizophrenia. Trials were eligible if they included patients with treatment-resistant schizophrenia and had a duration of at least 6 weeks. IPD were requested from trial investigators. The primary outcome was change in overall schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) between clozapine and other second-generation antipsychotics after 6-8 weeks of treatment. The effect size measure for the primary outcome was mean difference with 95% credible interval (CrI). We fitted a Bayesian random-effects IPD meta-regression model that included duration of illness, baseline severity, and sex as potential prognostic factors or treatment effect modifiers. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). People with lived experience of mental illness were involved in this study. This study is registered with PROSPERO, CRD42021254986. FINDINGS: We screened 13 876 references and included 19 studies with data for 1599 participants; IPD were available for 12 of 19 trials (n=1052; mean age 37·67 years [SD 11·24; range 10-66]; 348 [33·08%] women and 704 [66·92%] men). Data on ethnicity were not available. The estimated mean difference in change from baseline PANSS total score was -0·64 points (95% CrI -3·97 to 2·63; τ=2·68) in favour of other second-generation antipsychotics. Shorter duration of illness and higher baseline severity were prognostic factors associated with a larger reduction in symptoms, but neither those factors nor sex were found to modify the relative effect between clozapine and other second-generation antipsychotics. The confidence in the evidence was graded as very low. INTERPRETATION: This IPD meta-analysis found a small and uncertain advantage of other second-generation antipsychotics, mainly olanzapine and risperidone, and so did not provide evidence for superior efficacy of clozapine compared with other second-generation antipsychotics in treatment-resistant schizophrenia. It is limited by unavailability of IPD for some studies, uncaptured sources of variance, and uncertainty due to premature study discontinuation. Given the side-effects of clozapine, the observed uncertainty regarding clozapine's superiority warrants prudent use and further research. FUNDING: German Ministry of Education and Research.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a klozapin $x terapeutické užití $7 D003024
- 650 12
- $a antipsychotika $x terapeutické užití $7 D014150
- 650 12
- $a refrakterní schizofrenie $x farmakoterapie $7 D000090663
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a metaanalýza $7 D017418
- 700 1_
- $a Hamza, Tasnim $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Bern, Switzerland
- 700 1_
- $a Chalkou, Konstantina $u Department of Clinical Research, University of Bern, Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 700 1_
- $a Siafis, Spyridon $u Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany; German Center for Mental Health, Munich, Germany
- 700 1_
- $a Dong, Shimeng $u Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany; German Center for Mental Health, Munich, Germany
- 700 1_
- $a Bighelli, Irene $u Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany; German Center for Mental Health, Munich, Germany
- 700 1_
- $a Hansen, Wulf-Peter $u Bündnis für psychisch erkrankte Menschen, Munich, Germany
- 700 1_
- $a Scheuring, Elfriede $u Bündnis für psychisch erkrankte Menschen, Munich, Germany
- 700 1_
- $a Davis, John M $u Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA; Maryland Psychiatric Research Center, Baltimore, MD, USA
- 700 1_
- $a Priller, Josef $u Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany; German Center for Mental Health, Munich, Germany; Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité Medical University Berlin and German Center for Neurodegenerative Diseases, Berlin, Germany; University of Edinburgh and UK Dementia Research Institute, Edinburgh, UK
- 700 1_
- $a Baumann, Pierre $u Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly-Lausanne, Switzerland
- 700 1_
- $a Conley, Robert $u Beckley Psytech, Oxford, UK; School of Medicine, University of Maryland, Baltimore, MD, USA
- 700 1_
- $a Cordes, Joachim $u Department of Psychiatry and Psychotherapy, Florence Nightingale Hospital, Düsseldorf, Germany
- 700 1_
- $a Kelly, Deanna $u Maryland Psychiatric Research Center, Baltimore, MD, USA
- 700 1_
- $a Kluge, Michael $u Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Rudolf-Virchow-Klinikum Glauchau, Glauchau, Germany
- 700 1_
- $a Kumra, Sanjiv $u Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN, USA
- 700 1_
- $a Lewis, Shôn $u Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
- 700 1_
- $a Meltzer, Herbert Y $u Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, USA
- 700 1_
- $a Naber, Dieter $u Department of Psychiatry and Psychotherapy, Hamburg-Eppendorf University, Hamburg, Germany
- 700 1_
- $a Schooler, Nina $u SUNY Downstate Health Sciences Center, New York, NY, USA
- 700 1_
- $a Volavka, Jan $u Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Wahlbeck, Kristian $u Finnish Institute for Health and Welfare, Helsinki, Finland
- 700 1_
- $a Salanti, Georgia $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 700 1_
- $a Leucht, Stefan $u Department of Psychiatry and Psychotherapy, School of Medicine and Health, Technical University of Munich, Munich, Germany; German Center for Mental Health, Munich, Germany. Electronic address: stefan.leucht@tum.de
- 773 0_
- $w MED00193477 $t The lancet. Psychiatry $x 2215-0374 $g Roč. 12, č. 4 (2025), s. 254-265
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40023172 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135434 $b ABA008
- 999 __
- $a ok $b bmc $g 2310979 $s 1246409
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 12 $c 4 $d 254-265 $e 20250226 $i 2215-0374 $m The lancet. Psychiatry $n Lancet Psychiatry $x MED00193477
- LZP __
- $a Pubmed-20250415
